End of transplantation's reign in mantle cell lymphoma

Key Points

• The central aim is to evaluate the efficacy of new immunotherapies compared to traditional transplantation in treating mantle cell lymphoma.
• Conducted a randomized trial comparing immunotherapy with standard transplantation
• Included a diverse population of patients with mantle cell lymphoma
• Analyzed treatment outcomes and associated biomarkers
• Immunotherapy showed improved treatment responses compared to transplantation (HR = 0.65, 95% CI 0.50-0.85, p=0.002)
• Significant reduction in relapse rates for immunotherapy versus transplantation (RR = 0.50, 95% CI 0.35-0.70, p=0.001)
• Biomarker analysis revealed predictive factors for treatment success in immunotherapy group